PL397776A1 - Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową oraz kompozycja obejmująca ten kompleks - Google Patents

Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową oraz kompozycja obejmująca ten kompleks

Info

Publication number
PL397776A1
PL397776A1 PL397776A PL39777602A PL397776A1 PL 397776 A1 PL397776 A1 PL 397776A1 PL 397776 A PL397776 A PL 397776A PL 39777602 A PL39777602 A PL 39777602A PL 397776 A1 PL397776 A1 PL 397776A1
Authority
PL
Poland
Prior art keywords
hiv
complex
chaperone
soluble
surface glycoprotein
Prior art date
Application number
PL397776A
Other languages
English (en)
Other versions
PL218245B1 (pl
Inventor
Christian Scholz
Herbert Andres
Elke Faatz
Alfred Engel
Dorothea Sizmann
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL397776A1 publication Critical patent/PL397776A1/pl
Publication of PL218245B1 publication Critical patent/PL218245B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
PL397776A 2001-06-22 2002-06-24 Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową i izomerazę peptydyloprolilową oraz kompozycja reagentów obejmująca ten kompleks PL218245B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01115225 2001-06-22
EP01120939 2001-08-31

Publications (2)

Publication Number Publication Date
PL397776A1 true PL397776A1 (pl) 2012-07-16
PL218245B1 PL218245B1 (pl) 2014-10-31

Family

ID=26076626

Family Applications (2)

Application Number Title Priority Date Filing Date
PL367679A PL215170B1 (pl) 2001-06-22 2002-06-24 Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych
PL397776A PL218245B1 (pl) 2001-06-22 2002-06-24 Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową i izomerazę peptydyloprolilową oraz kompozycja reagentów obejmująca ten kompleks

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL367679A PL215170B1 (pl) 2001-06-22 2002-06-24 Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych

Country Status (16)

Country Link
US (2) US7244819B2 (pl)
EP (3) EP1402015B1 (pl)
JP (6) JP4174422B2 (pl)
KR (2) KR100702373B1 (pl)
CN (1) CN100510068C (pl)
AT (2) ATE522603T1 (pl)
AU (2) AU2002317841A1 (pl)
BR (1) BRPI0210598B8 (pl)
CA (3) CA2770453C (pl)
DE (1) DE60233942D1 (pl)
DK (2) DK2267452T3 (pl)
ES (3) ES2372031T3 (pl)
HK (1) HK1068918A1 (pl)
MX (1) MXPA03011455A (pl)
PL (2) PL215170B1 (pl)
WO (2) WO2003000877A2 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE522603T1 (de) * 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
US20050130259A1 (en) * 2002-06-25 2005-06-16 Akira Ideno Expression vector, host, fused protein, process for producing fused protein and process for producing protein
WO2004047869A1 (en) * 2002-11-26 2004-06-10 Danmarks Fødevareforskning Dendrimer conjugates for selective of protein aggregates
US20070026501A1 (en) * 2003-04-18 2007-02-01 Joe Chiba Immunogen, composition for immulogical use and process for producing antibody using the same
JP5631533B2 (ja) * 2004-12-23 2014-11-26 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ 遺伝子発現技術
CA2562738C (en) 2005-10-26 2011-07-12 F. Hoffmann-La Roche Ag Soluble rubella e1 envelope antigens
CN101351550B (zh) * 2006-01-03 2012-10-10 霍夫曼-拉罗奇有限公司 具有卓越的伴侣和折叠活性的嵌合融合蛋白
WO2007141650A2 (en) * 2006-01-17 2007-12-13 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection
EP2024520B1 (en) 2006-05-11 2014-03-05 Becton, Dickinson and Company Method of protein extraction from cells
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
ES2372359T3 (es) 2007-04-20 2012-01-19 F. Hoffmann-La Roche Ag Detección de infecciones primarias por patógenos.
WO2009031852A2 (en) * 2007-09-06 2009-03-12 Korea University Industry and Academy Cooperation Foundation Preparation method of recombinant protein by use of a fusion expression partner
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5461423B2 (ja) 2007-12-13 2014-04-02 エフ．ホフマン−ラ ロシュ アーゲー 新規風疹ｅ１エンベロープタンパク質変異体および抗風疹抗体の検出におけるその使用
EP2127678A1 (en) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA as a tool for recombinant protein and enzyme technology
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
DK2670847T3 (en) 2011-02-03 2017-01-16 Xoma Technology Ltd Methods and Materials for Improving Functional Protein Expression in Bacteria
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2617731A1 (en) 2012-01-19 2013-07-24 Roche Diagnostics GmbH Soluble immunoreactive Treponema pallidum TpN47 antigens
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2706115A1 (en) * 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperone-chaperone fusion polypeptides for reduction of interference and stabilization of immunoassays
WO2014072305A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4
EP2917388B1 (en) 2012-11-08 2016-10-05 Roche Diagnostics GmbH Nucleic acids encoding chimeric polypeptides for library screening
AR093378A1 (es) 2012-11-08 2015-06-03 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
EP2827146A1 (en) 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP2913338A1 (en) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
JP2015215244A (ja) * 2014-05-12 2015-12-03 富士レビオ株式会社 免疫測定における抗ｈｔｌｖ抗体の検出感度を向上させる方法
CN106459207B (zh) 2014-05-14 2020-07-10 豪夫迈·罗氏有限公司 结合HER3β-发夹的抗HER3抗体
MX2016014862A (es) 2014-05-14 2017-02-27 Hoffmann La Roche Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
WO2016089782A1 (en) * 2014-12-01 2016-06-09 Pfenex Inc. Fusion partners for peptide production
EP3257941A4 (en) * 2015-02-13 2018-07-04 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3390424B1 (en) * 2015-12-15 2021-09-01 Roche Diagnostics GmbH Fkbp domain with transglutaminase recognition site
EP3465217A1 (en) 2016-05-31 2019-04-10 Roche Diagnostics GmbH Method for serological detection of viral antigens
ES2796479T3 (es) 2016-05-31 2020-11-27 Hoffmann La Roche Procedimiento de pretratamiento para la detección rápida del antígeno central del VHC
US10815472B2 (en) 2016-06-20 2020-10-27 Metgen Oy Method for obtaining active insoluble xylose isomerase
ES2865511T3 (es) 2017-02-02 2021-10-15 Hoffmann La Roche Inmunoanálisis que usa al menos dos agentes de unión específica a analito pegilado
JP2020517647A (ja) 2017-04-26 2020-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 可溶性および免疫反応性のジカウイルスｎｓ１ポリペプチド
EP3658171B1 (en) 2017-07-27 2023-08-30 Roche Diagnostics GmbH Multi-epitope fusion protein of an hcv antigen and uses thereof
CN110066343B (zh) * 2019-05-23 2021-04-09 北京新创生物工程有限公司 一种用于检测hiv新发感染的重组抗原及其应用
EP4139684A1 (en) 2020-04-23 2023-03-01 F. Hoffmann-La Roche AG Corona nucleocapsid antigen for use in antibody-immunoassays
EP4380955A1 (en) 2021-08-06 2024-06-12 Roche Diagnostics GmbH Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
WO2023213758A1 (en) 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Hiv gp41 variants for immunodiagnostic assays

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4735896A (en) 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
DE3705686C2 (de) 1987-02-23 1995-11-30 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Antikörpern
NZ224663A (en) 1987-05-28 1990-11-27 Amrad Corp Ltd Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors
SE8704185L (sv) 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
DE69223250T3 (de) 1991-06-14 2008-02-28 Idexx Laboratories, Inc. Detektion des immunschwäche-virus aus felis
WO1993013200A1 (en) * 1991-12-20 1993-07-08 Novo Nordisk A/S A process for the preparation of lipase
CA2133826A1 (en) 1992-04-09 1993-10-28 James L. Gallarda Assay for detection of hiv antigen and hiv antibody
WO1993025533A1 (en) 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
DK0663010T3 (da) 1992-10-02 2000-11-13 Res Corp Technologies Inc Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
US5459051A (en) 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
EP0785992A4 (en) 1994-10-25 1999-12-22 Univ Leland Stanford Junior TRANSFORMATION OF THE STATE OF CELLS PRODUCED BY GENETIC ENGINEERING
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
JP2000501171A (ja) 1995-09-15 2000-02-02 メルク エンド カンパニー インコーポレーテッド 融合タンパク質を用いるハイスループットアッセイ
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9614114D0 (en) 1996-07-05 1996-09-04 Amcor Packaging Uk Ltd New packages
EP0928336A1 (en) 1996-09-26 1999-07-14 Medical Research Council Chaperone fragments
US6225082B1 (en) 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
US5989868A (en) * 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
DE19913117A1 (de) * 1998-05-06 1999-11-11 Roche Diagnostics Gmbh Entstörung durch Rheumafaktoren
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
ATE348177T1 (de) * 1998-10-02 2007-01-15 Vadeco Biotech Gmbh & Co Kg Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus
JP2002529081A (ja) 1998-11-06 2002-09-10 プレジデント アンド フェローズ オブ ハーバード カレッジ 生物学的事象のｆｋ５０６に基づく調節
AU3305100A (en) 1999-03-17 2000-10-04 Medical Research Council Method for refolding molecules of polypeptides containing ig domains
CA2372199A1 (en) 1999-05-14 2000-11-23 Medical Research Council Oligomeric chaperone proteins
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
EP1267919A2 (en) 2000-03-17 2003-01-02 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
JP2002262883A (ja) * 2001-03-13 2002-09-17 Sekisui Chem Co Ltd モノクローナル抗体の製造方法
ATE522603T1 (de) * 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält

Also Published As

Publication number Publication date
KR20060027871A (ko) 2006-03-28
KR100702373B1 (ko) 2007-04-02
JP4309910B2 (ja) 2009-08-05
BRPI0210598B1 (pt) 2018-11-13
US8426167B2 (en) 2013-04-23
EP2267452A1 (en) 2010-12-29
MXPA03011455A (es) 2004-04-05
DK1402015T3 (da) 2011-12-05
JP4262594B2 (ja) 2009-05-13
ES2333108T3 (es) 2010-02-17
JP2007322436A (ja) 2007-12-13
PL215170B1 (pl) 2013-10-31
JP2009102320A (ja) 2009-05-14
AU2002317841A1 (en) 2003-01-08
PL218245B1 (pl) 2014-10-31
ES2372031T3 (es) 2012-01-13
CN100510068C (zh) 2009-07-08
JP2007125026A (ja) 2007-05-24
US7244819B2 (en) 2007-07-17
BRPI0210598B8 (pt) 2021-05-25
AU2002325265B2 (en) 2006-10-19
JP2009100770A (ja) 2009-05-14
CA2770453A1 (en) 2003-01-03
CA2449747C (en) 2010-04-13
US20090028893A1 (en) 2009-01-29
EP2267452B8 (en) 2012-11-14
WO2003000877A3 (en) 2003-10-30
DE60233942D1 (de) 2009-11-19
WO2003000878A3 (en) 2003-10-09
JP4320351B2 (ja) 2009-08-26
US20030096352A1 (en) 2003-05-22
KR20040010774A (ko) 2004-01-31
CN1524123A (zh) 2004-08-25
EP1402041B1 (en) 2009-10-07
JP2004534831A (ja) 2004-11-18
ATE445016T1 (de) 2009-10-15
JP4523660B2 (ja) 2010-08-11
EP2267452B1 (en) 2012-07-25
BR0210598A (pt) 2004-07-20
EP1402015B1 (en) 2011-08-31
ATE522603T1 (de) 2011-09-15
HK1068918A1 (en) 2005-05-06
JP2004535195A (ja) 2004-11-25
CA2450476C (en) 2012-05-15
KR100611545B1 (ko) 2006-08-10
DK2267452T3 (da) 2012-10-29
WO2003000878A2 (en) 2003-01-03
EP1402041A2 (en) 2004-03-31
ES2391623T3 (es) 2012-11-28
EP1402015A2 (en) 2004-03-31
CA2770453C (en) 2014-12-09
CA2449747A1 (en) 2003-01-03
CA2450476A1 (en) 2003-01-03
PL367679A1 (pl) 2005-03-07
WO2003000877A2 (en) 2003-01-03
JP4174422B2 (ja) 2008-10-29

Similar Documents

Publication Publication Date Title
PL397776A1 (pl) Kompleks rozpuszczalny obejmujący retrowirusową glikoproteinę powierzchniową oraz kompozycja obejmująca ten kompleks
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
DE60037450D1 (de) Funf-helix protein
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
DZ3008A1 (fr) Inhibiteurs de l'aspartyle protéase.
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
JP2002508338A5 (pl)
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
FR2819809B1 (fr) Peptides presentant un affinite pour la proteine virale gp120, et utilisation de ces peptides
WO2003052122A3 (en) Gp41 inhibitor
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2002059258A3 (en) Chimeric proteins for prevention and treatment of hiv infection
FR2874612A1 (fr) Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
TH87273A (th) วัคซีน
TH87273B (th) วัคซีน
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie
RU97103671A (ru) Способ диагностики иммунодефицита при вич-инфекции